SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue slipped marginally during the June 2025 quarter. A decline of about Rs. 8048.30 millions was observed as compared to Rs. 8110.00 millions during the corresponding quarter last year.The Company has registered profit of Rs. 2047.00  millions for the quarter ended June 2025, a growth of 12.69%  over Rs. 1816.50 millions millions achieved in the corresponding quarter of last year.The company reported a good operating profit of 2945.10 millions compared to 2652.70 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 8048.30 8110.00 -0.76 8048.30 8110.00 -0.76 37234.90 34072.50 9.28
Other Income 437.60 358.50 22.06 437.60 358.50 22.06 1425.60 1234.80 15.45
PBIDT 2945.10 2652.70 11.02 2945.10 2652.70 11.02 13118.50 10241.30 28.09
Interest 4.20 3.70 13.51 4.20 3.70 13.51 13.10 18.00 -27.22
PBDT 2940.90 2649.00 11.02 2940.90 2649.00 11.02 13152.30 8787.20 49.68
Depreciation 155.20 164.10 -5.42 155.20 164.10 -5.42 667.90 696.80 -4.15
PBT 2785.70 2484.90 12.11 2785.70 2484.90 12.11 12484.40 8090.40 54.31
TAX 738.70 668.40 10.52 738.70 668.40 10.52 3293.80 2243.50 46.82
Deferred Tax 0.20 35.10 -99.43 0.20 35.10 -99.43 62.00 -113.60 -154.58
PAT 2047.00 1816.50 12.69 2047.00 1816.50 12.69 9190.60 5846.90 57.19
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 36.59 32.71 11.87 36.59 32.71 11.87 35.23 30.06 17.21

Glaxosmithkline Phar Share Price

2393.25 32.95 (1.40%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×